profit from every $100 of sales.
$0$100
Delcath Systems
$21.38-1.79% today
+148.9% in 1 year
1-year low $8.191-year high $21.77
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $275.47 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Delcath Systems sold, what it kept, and what it did with the cash.
Sales went from $2.72 million in 2022 to $85.2 million in 2025, with $2.70 million of profit last year.
SalesProfit
Delcath Systems handed back 29% of the cash it generated last year.
Buybacks $6M
Free cash flow 2025$21M
Bought back its own shares$6M
Paid as dividends–
Cash vs. debt$43M vs. $936,000
Delcath Systems vs. similar companies
Delcath Systems grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Delcath Systems | 275.5× · Very expensive | ||
 Abbott Laboratories | 28.5× · Fair price | ||
 Medtronic | 26.9× · Fair price | ||
 Stryker | 36.6× · Expensive | ||
 Edwards Lifesciences | 56.7× · Expensive |
AI analysis
An AI analyst reads Delcath Systems's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3 | 2 | 37 | 85 | |
| 2 | 1 | 31 | 73 | |
| -34 | -38 | -12 | 1 | |
| -34 | -38 | -12 | 1 | |
| -37 | -48 | -26 | 3 | |
| -4.12 | -2.94 | -0.93 | 0.07 | |
| 74.8% | 69.2% | 83.4% | 86.2% | |
| -1,245.1% | -1,849.0% | -33.4% | 0.8% | |
| -1,342.7% | -2,308.9% | -70.9% | 3.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 18 | 39 | 77 | 124 |
| Cash | 8 | 13 | 32 | 43 |
| Total debt | 16 | 10 | 1 | 1 |
| Total liabilities | 24 | 23 | 8 | 12 |
| -6 | 16 | 69 | 111 | |
| 16 | 16 | 29 | 36 | |
| -266.8% | -116.2% | -14.0% | 0.5% | |
| 623.1% | -302.2% | -38.4% | 2.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -25 | -31 | -19 | 23 | |
| 0 | 0 | 1 | 2 | |
| -25 | -31 | -19 | 21 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 6 | |
| 8 | 8 | 10 | 24 |
Valuation
- 275.5×
- –
- –
- 4.4×
- 8.7×
- 35.5×
- 695.0×
- 2.8%
- 0.4%
- 0.0%
Profitability
- 86.2%
- 0.8%
- 3.2%
- 0.4%
- 0.5%
- -101.7%
- 0.5%
- 0.4%
- -1.4%
- 37.7%
Growth
- +215.3%
- –
- +209.0%
- –
- +30.2%
Financial health
- -42.1×
- 0.01
- 0.7%
- –
- 10.92
- 10.33
- 0.72
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 36%of 952
Bottom 29%of 883
Bottom 1%of 576
Top 1%of 870
Top 37%of 985
What analysts expect
- Average price target
- $23.00
- Range
- $19.00 – $27.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.03 | -0.09 | +68.1% |
| Feb 26, 2026 | -0.05 | -0.06 | +20.6% |
| Nov 4, 2025 | 0.02 | 0.02 | +0.0% |
| Aug 6, 2025 | 0.07 | 0.03 | +169.2% |
| May 8, 2025 | 0.03 | 0.10 | −70.0% |
| Mar 6, 2025 | 0.05 | -0.10 | +150.0% |
| Nov 8, 2024 | -0.03 | -0.13 | +76.9% |
| Aug 5, 2024 | -0.48 | -0.34 | −41.2% |
News
Delcath Systems, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 9, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
42No pass
Philip Fisher
37No pass
Peter Lynch
68Pass
Joel Greenblatt
3No pass
Charlie Munger
36No pass
Terry Smith
36No pass
Questions about Delcath Systems
Is Delcath Systems a good stock to buy?
A business with weak numbers, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Delcath Systems AI analysis
What does Delcath Systems do?
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. It is in Medical Devices.
Does Delcath Systems pay a dividend?
No. Delcath Systems does not pay a dividend at the moment; in 2025 it returned $6.00 million to shareholders by buying back its own shares.
Is Delcath Systems stock halal?
Yes. Delcath Systems passes our halal screen: its business is permitted and its debt is 0.1% of its market value, under the 30% limit. How we check
How has Delcath Systems stock done over the past year?
Up 148.9% over the past twelve months, to $21.38. It traded between $8.19 and $21.77, close to its high.
Who are Delcath Systems's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Delcath Systems's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.